Beechtree Labs has chosen Curavit Clinical Research for a fully decentralized clinical trial to investigate a Covid-19 therapy. The FDA-authorized phase 2 clinical study will evaluate the effect of Beech Tree's BTL-TML therapy on mean duration and severity of disease in 40 outpatients aged 60 years or older with underlying conditions. The study also assesses the safety of BTL-TML over 10 days of treatment and an additional four days of follow-up.

The trial is a fully decentralized clinical trial, made possible by applying virtual trial design protocols, digital telehealth technologies, electronic patient reported outcomes (ePRO), and full web and contact center patient support to eliminate the need for in-person office visits.

"We chose Curavit because of their exclusive focus on designing and executing virtual trials. We needed a company with Curavit's expertise in this important new discipline of clinical research in order to make this trial possible," Thomas Hatch, Director of Business Development at Beech Tree said. "This is a unique opportunity to apply modern trial design and telehealth technologies to allow patients to participate in this study without the potential risk of traveling to physical sites and to participate from the safety and comfort of their own homes."